跳至主要内容
临床试验/NCT00595231
NCT00595231已完成2 期

A Multi-Center,Randomized, Double-Blind, Placebo-Controlled, Phase 2, Exploratory Study to Evaluate the Effect of Rufinamide on Anxiety in Patients With Moderate to Severe Generalized Anxiety Disorder

Biotie Therapies Inc.2 个研究点 分布在 1 个国家目标入组 239 人开始时间: 2008年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
239
试验地点
2
主要终点
Change From Baseline in Covi Anxiety Scale (CAS) - Index Total Score: Summary Statistics Observed

研究概览

简要总结

A Multi-Centered Randomized, Double-Blind, Placebo-Controlled, Phase 2, Exploratory Study to Evaluate the Effect of Rufinamide on Anxiety in Patients with Moderate to Severe Generalized Anxiety Disorder.

详细描述

This was an exploratory study to evaluate the effect of 500 or 1000 mg per day for 8 weeks of Rufinamide compared to placebo on measures of anxiety in patients with Generalized Anxiety Disorder, and to determine tolerability of Rufinamide in this population.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Outpatient 18-65
  • Meet Diagnostic and Statistical Manual,(DSM) IV criteria for GAD
  • Have moderate to severe anxiety
  • Sign IRB (Institutional Review Board) approved consent and can comply with visits and procedures
  • Women of childbearing potential must use acceptable method of contraception

排除标准

  • Have diagnosis of adjustment disorder or anxiety disorder Not otherwise specified (NOS)
  • Have diagnosis of specific phobia
  • Have diagnosis of antisocial personality disorder or other Axis II Disorder
  • Have diagnosis of substance abuse disorder within 3 months of study entry
  • Have diagnosis of major depressive disorder or panic disorder within 6 months of study entry
  • Have diagnosis of PTSD, eating disorder substance dependence disorder within 12 months of study entry
  • Have diagnosis anytime during lifetime of schizophrenia or other psychotic disorder, bipolar mood disorder, Obsessive-Compulsive Disorder (OCD), psychosurgery
  • Require medication to treat GAD other than study medication
  • Failed to show improvement with past treatment for GAD
  • Excessively consume caffeine
  • Are receiving treatment with prohibited medications
  • Uncontrolled thyroid condition
  • Positive urine drug screen
  • Clinically significant ECG finding
  • Participating in other clinical trial
  • Clinically significant out of range lab value
  • Past exposure to rufinamide
  • Pregnant or nursing females

研究组 & 干预措施

SYN111

Experimental

500 mg 1 week, followed by 1000 mg for 7 weeks

干预措施: SYN111 (Drug)

Placebo

Placebo Comparator

0 mg tablets

干预措施: Placebo (Drug)

结局指标

主要结局

Change From Baseline in Covi Anxiety Scale (CAS) - Index Total Score: Summary Statistics Observed

时间窗: 8 weeks

The Covi Anxiety Scale is a simple 3 item scale for the assessment of severity of anxiety symptoms. The scale measures 3 dimensions: verbal report, behavior and somatic symptoms of anxiety. Each item scored on a scale of 1 - 5. (1)not at all, (2)somewhat, (3)moderately, (4) considerably, and (5)very much), hence the scale is a 5- to 15 point range. The three items are the patient's verbal report (feeling shaky, jittery, jumpy), observed behavior consistent with anxiety during the interview (e.g. appearing frightened, shaky, restless) and somatic complains (e.g., sweating, trembling, heart pounding). COVI Rating Scale total score is the sum of items 1 - 3.

Change From Baseline in Hamilton Anxiety Scale (HAMA) - Total Score: Summary Statistics - Observed

时间窗: 8 Weeks

The Hamilton Anxiety Scale is a 14-item test measuring the severity of anxiety symptoms. It provides measures of overall anxiety, psychic anxiety (mental agitation and psychological distress), and somatic anxiety (physical complaints related to anxiety). The interviewer then rated the individuals on a 5-point scale for each of the 14 items. Seven of the items specifically address psychic anxiety and the remaining 7 items address somatic anxiety. The total anxiety score ranges from 0 to 56. The 7 psychic anxiety items elicit a psychic anxiety score that ranges from 0 to 28. The remaining 7 items yield a somatic anxiety score that also ranges from 0 to 28. A score of 17 or less indicates mild anxiety severity. A score from 18 to 24 indicates mild to moderate anxiety severity, a score of 25 to 30 indicates a moderate to severe anxiety and lastly a score of 31-56 is very severe. HAM-A total score is the sum of items 1 - 14.

Change From Baseline in Hospital Anxiety and Depression Scale (HADS). Summary Statistics

时间窗: 8 Weeks

The Hospital Anxiety and Depression Scale is a self screening questionnaire for depression and anxiety. It consists of 14 questions, seven for anxiety and seven for depression. The 14 statements are relevant to either generalized anxiety (7 statements) or 'depression' (again 7). Each question has 4 possible responses. Responses are scored on a scale from 3 to 0. The maximum score is therefore 21 for depression and 21 for anxiety. A score of 11 or higher indicates the probable presence of the mood disorder with a score of 8 to 10 being just suggestive of the presence of the respective state. The 2 subscales, anxiety and depression, have been found to be independent measures. In its current form the HADS is now divided into 4 ranges: normal (0-7), mild (8-10), moderate (11-15) and severe (16-21). Anxiety score = sum of items 1, 3, 5, 7, 9, 11, and 13. Depression score = sum of items 2, 4, 6, 8, 10, 12, and 14.

Change From Baseline in Montgomery-Asberg Depression Scale (MADRS) Summary Statistics.

时间窗: 8 Weeks

The MADRS (Montgomery and Asberg 1979) is a clinician-rated instrument that measures the presence and severity of depression. This instrument consists of 10 items. Each item is rated on a defined step scale of 0 to 6 with anchors at 2-point intervals. The MADRS total score is the sum of the 10 items and ranges from 0 to 60. A high numeric rating shows a greater degree of symptom severity.

Change From Baseline in Clinical Global Impression Scale for Severity of Illness: (CGI-S)

时间窗: 8 weeks

Severity of illness is the first scale in the CGI. A rating is filled in by the investigator at the start of treatment based on a 0-7 point weighted scale. It goes from not assessed (0), to among the most extremely ill patients (7).

Change From Baseline Raskin Depression Scale.

时间窗: 8 weeks

It explores the extent to which an individual demonstrates depression on three sub-scales (rated 1-5): verbal self-report, behavior and secondary symptoms of depression. Scores range from 3-15, with higher scores indicating greater severity.

次要结局

未报告次要终点

研究者

发起方
Biotie Therapies Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Exploratory Study to Evaluate the Effect of SYN111... | 临床试验